[
  {
    "ts": null,
    "headline": "AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE",
    "summary": "Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday, May 21, 2025. Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
    "url": "https://finnhub.io/api/news?id=fdea7f51af637be70a79896c0ed11e8923e14b7fe72e7426fb433d33afec1bae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747425660,
      "headline": "AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE",
      "id": 134567892,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday, May 21, 2025. Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
      "url": "https://finnhub.io/api/news?id=fdea7f51af637be70a79896c0ed11e8923e14b7fe72e7426fb433d33afec1bae"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (NasdaqGS:AMGN) Faces US$407 Million Verdict Over Antitrust Violations",
    "summary": "Amgen (NasdaqGS:AMGN) recently faced a legal setback, with a U.S. District Court jury finding the company liable for antitrust violations and awarding Regeneron Pharmaceuticals $406.8 million in damages. Despite this outcome, Amgen's stock price remained flat over the past week, even as the broader market saw significant gains, with the S&P 500 and Dow Jones both climbing steadily. This legal decision and possible concerns about competition might have countered the general positive market...",
    "url": "https://finnhub.io/api/news?id=3014cb8aee864baa02c2b8c0dd9e7908a38ec983613f574431f64c767e3fb952",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747416629,
      "headline": "Amgen (NasdaqGS:AMGN) Faces US$407 Million Verdict Over Antitrust Violations",
      "id": 134567893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NasdaqGS:AMGN) recently faced a legal setback, with a U.S. District Court jury finding the company liable for antitrust violations and awarding Regeneron Pharmaceuticals $406.8 million in damages. Despite this outcome, Amgen's stock price remained flat over the past week, even as the broader market saw significant gains, with the S&P 500 and Dow Jones both climbing steadily. This legal decision and possible concerns about competition might have countered the general positive market...",
      "url": "https://finnhub.io/api/news?id=3014cb8aee864baa02c2b8c0dd9e7908a38ec983613f574431f64c767e3fb952"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=01fb5af4c9091750e1297656893e69238aa3b7558b9ed44c95b7045631e25d74",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747413300,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 134534590,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=01fb5af4c9091750e1297656893e69238aa3b7558b9ed44c95b7045631e25d74"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price",
    "summary": "Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.",
    "url": "https://finnhub.io/api/news?id=8bbb3c23069a29fce289fbaaa27ca4e5be52498ccd00fecdf66efd86c9743dd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747407647,
      "headline": "Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price",
      "id": 134567764,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.",
      "url": "https://finnhub.io/api/news?id=8bbb3c23069a29fce289fbaaa27ca4e5be52498ccd00fecdf66efd86c9743dd2"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price",
    "summary": "Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.",
    "url": "https://finnhub.io/api/news?id=877bc09696e8f170a9d6d280e99f7a2a4dab17a4ef23d09e511e249658d289f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747407647,
      "headline": "Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price",
      "id": 134498545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.",
      "url": "https://finnhub.io/api/news?id=877bc09696e8f170a9d6d280e99f7a2a4dab17a4ef23d09e511e249658d289f4"
    }
  },
  {
    "ts": null,
    "headline": "Replimune Group: Analysts Are More Optimistic Than The Market",
    "summary": "Replimune Group shares fell 28% on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced melanoma. Read the latest REPL stock analysis here.",
    "url": "https://finnhub.io/api/news?id=bb77fd23fe6024b930fdae4bb9e7a6df8f78a2dbd277bd2fa5e0a398dacca4da",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747405350,
      "headline": "Replimune Group: Analysts Are More Optimistic Than The Market",
      "id": 134500847,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473708731/image_1473708731.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Replimune Group shares fell 28% on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced melanoma. Read the latest REPL stock analysis here.",
      "url": "https://finnhub.io/api/news?id=bb77fd23fe6024b930fdae4bb9e7a6df8f78a2dbd277bd2fa5e0a398dacca4da"
    }
  },
  {
    "ts": null,
    "headline": "Weight-loss drug developers line up to tap lucrative market as competition heats up",
    "summary": "Novo Nordisk and Eli Lilly, the leaders in the highly lucrative weight-loss drugsmarket, are competing against each other and several otherdrugmakers for next-generation treatments for obesity. ...",
    "url": "https://finnhub.io/api/news?id=63ec49153d6f25e9fe4e797402f0719a718a7bede435b1b2325d60e1d4b6fc93",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747403651,
      "headline": "Weight-loss drug developers line up to tap lucrative market as competition heats up",
      "id": 134500591,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Novo Nordisk and Eli Lilly, the leaders in the highly lucrative weight-loss drugsmarket, are competing against each other and several otherdrugmakers for next-generation treatments for obesity. ...",
      "url": "https://finnhub.io/api/news?id=63ec49153d6f25e9fe4e797402f0719a718a7bede435b1b2325d60e1d4b6fc93"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock",
    "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=97f8287fbfb211aa899e764c1f53f5c86747f1041b1f3edff0647449c7d1f459",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747400409,
      "headline": "Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock",
      "id": 134498740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=97f8287fbfb211aa899e764c1f53f5c86747f1041b1f3edff0647449c7d1f459"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff",
    "summary": "A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and the FDA scheduled an advisory meeting.",
    "url": "https://finnhub.io/api/news?id=4c19503761ecdbad37a505fbd071ae5971062de1487beb3ed376e4d10e1e98a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747391760,
      "headline": "Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff",
      "id": 134498741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and the FDA scheduled an advisory meeting.",
      "url": "https://finnhub.io/api/news?id=4c19503761ecdbad37a505fbd071ae5971062de1487beb3ed376e4d10e1e98a9"
    }
  }
]